Anlon Healthcare Reports Stellar Growth Amid Strategic Expansion

Anlon Healthcare Limited, an Indian pharmaceutical leader, announces a remarkable surge in revenue, profitability, and expansion in FY26. This performance is attributed to strategic acquisitions, increased global outsourcing, and India's favored position in global manufacturing. Anlon's diversified portfolio aims for continued growth and a 30% revenue CAGR over three years.

In a significant financial windfall, Anlon Healthcare Limited, one of India's foremost manufacturers of pharmaceutical intermediates and APIs, has declared substantial growth for FY26. Their audited results revealed a notable increase in revenue and profitability, driven by their robust R&D initiatives and strategic manufacturing expansions.

The company's consolidated income soared by 42.98% year-over-year to ₹172.22 Crores. Meanwhile, EBITDA saw a remarkable 47.55% rise to ₹47.77 Crores, and Profit After Tax (PAT) increased by 41.77% to ₹29.09 Crores. On the standalone front, total income climbed 46.32% to ₹176.26 Crores, EBITDA rose 43.27% to ₹46.39 Crores, and PAT grew 35.53% to ₹27.81 Crores.

Punitkumar Rasadia, Chairman & Managing Director, highlighted the enhanced demand for Anlon's pharmaceutical and API offerings, boosted by strategic acquisitions and market diversification, especially within the context of India's growing role in the global supply chain amid the China+1 strategy. Anlon’s future aims include expanding its portfolio and continuing sustainable growth with a focus on industrial chemicals and efficient production processes.